Shares of Moderna (NASDAQ: MRNA) jumped 7.8% to a record closing high of $348.83 on Friday after European health officials recommended authorizing the drugmaker's coronavirus vaccine for kids 12 and older. The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on Moderna's vaccine. The European Commission will now consider granting authorization for use in adolescents.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting